Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06421675 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06421675 · ClinicalTrials.gov record · last posted 2026-06-17

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

Study acronym: EMBRACE
StatusRecruiting
PhasePhase 2
Started2025-03-28
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
A phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously received at least three classes of therapeutic agents and are refractory to the last line of treatment. The primary objective of this study is to improve the tolerability and safety of elranatamab in patients with relapsed and/or refractory multiple myeloma by evaluating an outpatient and intermittent dosing strategy.

Amendment record 10 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 10 times since 2024-05-14; most recent amendment 2026-06-15. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-03-28
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT06421675
Lead Sponsor Ontario Clinical Oncology Group (OCOG)
Collaborators: Pfizer, McMaster University
Conditions Refractory Multiple Myeloma
Enrollment 40 participants
Start Date 2025-03-28
Primary Completion 2026-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-17